Xiaoshuang H. Niu

State Key Laboratory Of Antiviral Drugs
Zhengzhou, 450001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 30, 2026

A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.

A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

Respiratory Syncytial Virus (RSV) Prophylaxis: Clesrovimab and Beyond.

Respiratory Syncytial Virus (RSV) Prophylaxis: Clesrovimab and Beyond.

Journal: Journal of medicinal chemistry

Published: January 08, 2026

Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC.

Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC.

Journal: Trends in pharmacological sciences

Published: October 02, 2025

An oral vaccine based on stable peptide-chitosan conjugate targeting DEC-205 for cancer immunotherapy.

An oral vaccine based on stable peptide-chitosan conjugate targeting DEC-205 for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: August 07, 2025

Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.

Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.

Journal: Cell reports. Medicine

Published: June 02, 2025

Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy.

Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy.

Journal: Nano letters

Published: February 24, 2025

DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.

DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 28, 2025

VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis.

VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 18, 2024

Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.

Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.

Journal: Chembiochem : a European journal of chemical biology

Published: October 17, 2024

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.

Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: October 08, 2024

A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.

A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis.

Journal: Cancer immunology, immunotherapy : CII

Published: August 27, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026